New clinical data analysis confirms that the first-in-class direct renin inhibitor Rasilez® (aliskiren), known as Tekturna® in the US, provides significantly greater blood pressure reductions in obese patients with high blood pressure compared to the diuretic hydrochlorothiazide (HCT) alone1.
More: continued here
United Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary Lung Rx, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for inhaled treprostinil for the treatment of pulmonary arterial hypertension. The NDA will be subject to a standard review period of 10 months, with a targeted user fee deadline of April 30, 2009.
More: continued here
Blood pressure in low-birth-weight children younger than 3 years of age not only can be measured but should be, researchers at UT Southwestern Medical
More: continued here
SunTech Medical
More: continued here
Treatment of hypertension has proven to reduce cardiovascular risk substantially, but a large proportion of people with hypertension in the general population are not even diagnosed or treated. As a risk factor for stroke, ischemic brain lesions and silent brain infarcts, general atherosclerosis, myocardial infarction and cardiovascular morbidity, hypertension may also be a risk factor for dementia related to cerebrovascular disease.
More: continued here
The need for long term studies to establish the best means of treating Diabetes, was underlined by Prof John Cleland from the University of Hull at the ESC Congress in Munich. Prof Cleland listed the latest treatment available for patients and voiced his concern about the side-effects and efficacy of available anti-diabetic drugs.
More: continued here
Researchers in Canada working on an international study, discovered that the angiotensin-receptor blocker (ARB) telmisartan, a newer type of drug for lowering
More: continued here
An international study led by Canadian researchers has found that telmisartan, a medication used to lower blood pressure, reduced the outcome of cardiovascular death, heart attack or stroke in people who are unable to tolerate a widely available and effective standard treatment. Dr. Salim Yusuf and Dr. Koon Teo, professors in the Michael G. DeGroote School of Medicine at McMaster University and clinicians at Hamilton Health Sciences, led the study.
More: continued here
The Endocrine Society has released a new clinical practice guideline for the detection, diagnosis, and treatment of patients with primary aldosteronism. The guidelines appear in the September issue of the Journal of Clinical Endocrinology & Metabolism (JCEM), a publication of The Endocrine Society. Primary aldosteronism (PA) refers to conditions in which production of aldosterone, a steroid hormone produced in the adrenal gland, is inappropriately high.
More: continued here
Patients with chronic smoker’s bronchitis often suffer from increased pressure in the blood vessels supplying the lung (pulmonary hypertension). The blood pressure increases further during exercise and can lead to severe limitation of physical activity. In patients with other diseases causing pulmonary hypertension, for instance rheumatic or heart conditions, drug therapy has been shown to improve exercise capacity and decrease mortality.
More: continued here
